Assembly Biosciences, Inc (ASMB)

Price$26.92

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-40.62%

Price vs S&P 500 (4W)-3.91%

VGM Score47.68

Market Capitalization$439.59M

All Metrics

Book Value / Share (Quarterly)$12.50

P/TBV (Annual)0.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)65.83%

Cash Flow / Share (Quarterly)$-2.51

Price vs S&P 500 (YTD)-29.60%

Net Profit Margin (TTM)-8.98%

EPS (TTM)$-1.29

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-1.29

Revenue Growth (5Y)-1.78%

EPS (Annual)$-0.55

ROI (Annual)-2.96%

Net Profit Margin (5Y Avg)-631.81%

Cash / Share (Quarterly)$14.26

Revenue Growth QoQ (YoY)-12.80%

ROA (Last FY)-2.38%

Revenue Growth TTM (YoY)121.11%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-92.37%

Operating Margin (TTM)-19.05%

Cash Flow / Share (Annual)$-2.60

P/B Ratio2.21x

P/B Ratio (Quarterly)2.22x

Net Income / Employee (Annual)$-83,900

EV / Revenue (TTM)5.75x

Net Interest Coverage (TTM)-99.13x

ROA (TTM)-3.14%

EPS Incl Extra (Annual)$-0.55

Current Ratio (Annual)5.22x

Quick Ratio (Quarterly)6.49x

3-Month Avg Trading Volume0.12M

52-Week Price Return94.79%

Revenue / Employee (TTM)$973,900

Tangible BV / Share (Quarterly)$42.13

P/S Ratio (Annual)6.08x

Asset Turnover (Annual)0.28x

52-Week High$39.70

Operating Margin (5Y Avg)-656.41%

EPS Excl Extra (Annual)$-0.55

CapEx CAGR (5Y)-50.50%

Tangible BV CAGR (5Y)27.13%

26-Week Price Return-24.69%

Quick Ratio (Annual)5.11x

13-Week Price Return-6.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.65x

Enterprise Value$408.47M

Revenue / Share Growth (5Y)-24.79%

Asset Turnover (TTM)0.35x

Book Value / Share Growth (5Y)-31.24%

Revenue / Employee (Annual)$990,500

Pretax Margin (Annual)-8.47%

Cash / Share (Annual)$15.65

3-Month Return Std Dev49.47%

Net Income / Employee (TTM)$-87,400

ROE (Last FY)-2.96%

Net Interest Coverage (Annual)-98.91x

EPS Basic Excl Extra (Annual)$-0.55

P/FCF (TTM)30.93x

Receivables Turnover (TTM)148.47x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.29

Receivables Turnover (Annual)148.47x

ROI (TTM)-4.21%

P/S Ratio (TTM)6.18x

Pretax Margin (5Y Avg)-639.58%

Revenue / Share (Annual)$6.45

Tangible BV / Share (Annual)$42.13

Price vs S&P 500 (52W)66.58%

Year-to-Date Return-18.67%

5-Day Price Return-2.40%

EPS Normalized (Annual)$-0.55

ROA (5Y Avg)-48.05%

Net Profit Margin (Annual)-8.47%

Month-to-Date Return2.63%

Cash Flow / Share (TTM)$-1.41

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-16.76%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-92.37%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.29

P/TBV (Quarterly)0.66x

P/B Ratio (Annual)2.60x

Pretax Margin (TTM)-8.98%

Book Value / Share (Annual)$13.04

Price vs S&P 500 (13W)-16.27%

Beta1.08x

P/FCF (Annual)19.55x

Revenue / Share (TTM)$4.21

ROE (TTM)-4.21%

52-Week Low$13.81

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.54est. -0.58

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.30

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ASMBAssembly Biosciences, Inc	C	C	C	$26.92
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Assembly Biosciences is a clinical-stage biotechnology company developing two oral therapeutic platforms: one targeting hepatitis B virus (HBV) infection, and another addressing microbiome dysbiosis. Its lead HBV program employs proprietary core protein Allosteric Modulators—small molecules that inhibit multiple steps of the viral lifecycle to improve cure rates beyond current clinical standards. The HBV program constitutes the majority of the company's revenue.